[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100636845":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":31,"centralContacts":42,"locations":50,"responsibleParty":85,"collaborators":31,"id":87,"slug":88,"hasResults":89,"nctId":90,"briefTitle":91,"officialTitle":92,"acronym":31,"eligibilityCriteria":93,"healthyVolunteers":89,"sex":94,"minAge":95,"maxAge":31,"enrollmentInfo":96,"targetDuration":31,"studyType":99,"phases":100,"briefSummary":102,"conditions":103,"keywords":105,"overallStatus":53,"whyStopped":31,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"Novartis","INDUSTRY",[8,15,20],{"label":9,"type":10,"description":11,"interventionNames":12},"INR731 single agent (Arm A)","EXPERIMENTAL","The dose escalation part with single agent INR731 may be followed by a dose expansion part.",[13,14],"Drug: INR731","Drug: Androgen deprivation therapy (ADT)",{"label":16,"type":10,"description":17,"interventionNames":18},"INR731 in combination with enzalutamide (Arm B)","The dose escalation part with INR731 in combination with enzalutamide may be followed by a dose expansion part.",[13,19,14],"Drug: Enzalutamide",{"label":21,"type":10,"description":22,"interventionNames":23},"INR731 in combination with abiraterone (Arm C)","Dose escalation of INR731 in combination with abiraterone.",[13,24,14],"Drug: Abiraterone",[26,32,35,38],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"DRUG","INR731","Oral administration",[21,16,9],null,{"type":27,"name":33,"description":29,"armGroupLabels":34,"otherNames":31},"Enzalutamide",[16],{"type":27,"name":36,"description":29,"armGroupLabels":37,"otherNames":31},"Abiraterone",[21],{"type":27,"name":39,"description":40,"armGroupLabels":41,"otherNames":31},"Androgen deprivation therapy (ADT)","Background therapy. Patients will continue receiving ADT throughout this clinical study as part of the standard of care.",[21,16,9],[43,48],{"name":44,"role":45,"phone":46,"phoneExt":31,"email":47},"Novartis Pharmaceuticals","CONTACT","1-888-669-6682","novartis.email@novartis.com",{"name":44,"role":45,"phone":49,"phoneExt":31,"email":31},"+41613241111",[51,73],{"facility":52,"status":53,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"Mary Crowley Cancer Research","RECRUITING","Dallas","Texas","75251","United States","US",{"type":60,"coordinates":61},"Point",[62,63],-96.80667,32.78306,{"lat":63,"lon":62},[66,70],{"name":67,"role":45,"phone":68,"phoneExt":31,"email":69},"Pramitha Kondancheri","972-566-3000","Pramitha.RarothKondancheri@scri.com",{"name":71,"role":72,"phone":31,"phoneExt":31,"email":31},"Reva Schneider","PRINCIPAL_INVESTIGATOR",{"facility":74,"status":53,"city":75,"state":76,"zip":77,"country":78,"countryCode":79,"cosmosGeoPoint":80,"geoPoint":84,"contacts":31},"Novartis Investigative Site","Melbourne","Victoria","3000","Australia","AU",{"type":60,"coordinates":81},[82,83],144.96332,-37.814,{"lat":83,"lon":82},{"type":86,"investigatorFullName":31,"investigatorTitle":31,"investigatorAffiliation":31,"oldNameTitle":31,"oldOrganization":31},"SPONSOR","100636845","phase-1-a-study-to-investigate-the-safety-and-tolerability-of-oral-inr731-single-agent-or-in-combination-with-androgen-receptor-pathway-inhibitor-arpi-in-patients-with-metastatic-prostate-cancer-100636845",false,"NCT07570979","A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer","An Open-label, Multi-center, First in Human Phase I Global Dose Escalation and Expansion Study of INR731 Single Agent or in Combination With an Androgen Receptor Pathway Inhibitor in Patients With Metastatic Prostate Cancer","Inclusion Criteria:\n\n* An Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≤2.\n* Participants must have histological and\u002For cytological confirmation of adenocarcinoma of the prostate. Participants with mixed histology (neuroendocrine) are eligible as long as the non-adenocarcinoma feature is the minority component.\n* At least 1 metastatic lesion (according to local radiology assessment by the investigator) present on baseline CT, MRI, or bone scan imaging obtained ≤28 days prior to Cycle 1 Day 1 (C1D1).\n* Patients must have a castrate level of serum\u002Fplasma testosterone (\\\u003C50 ng\u002FdL or \\\u003C1.7 nmol\u002FL).\n* Ongoing androgen deprivation therapy (ADT) either via orchiectomy and\u002For ongoing gonadotropin-releasing hormone (GnRH) analog or inhibitor is allowed.\n* Participants must be mCRPC patients who have either progressed on or are not candidates for other SOC. Prior taxane, poly(ADP) ribose polymerase (PARP) inhibitor, and lutetium Lu 177 vipivotide tetraxetan (Pluvicto) are allowed. Combination expansion patients, however, must be 1L mCRPC with no prior treatment in the mCRPC setting. Treatment within the mHSPC setting does not affect eligibility.\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years old.\n* Histological and\u002For cytological confirmation of non-adenocarcinoma of the prostate.\n* Patients with biochemical recurrence only or those without evidence of metastatic disease by radiographical imaging (CT\u002FMRI or bone scan) are not eligible.\n* Patients previously treated with a cereblon-based degrader.\n* Patients who are HIV+ or immune compromised.\n* Use of agents known to prolong QT interval unless they can be permanently discontinued for the duration of the study\n* Treatment with an investigational agent within 7 days (or 5 half-lives, whichever is longer) of the anticipated Cycle 1 Day 1 (C1D1).\n\nOther protocol-defined inclusion\u002Fexclusion criteria may apply.","MALE","18 Years",{"count":97,"type":98},208,"ESTIMATED","INTERVENTIONAL",[101],"PHASE1","The purpose of this study is to assess the safety, tolerability, pharmacokinetics\u002Fpharmacodynamics, preliminary anti-tumor activity, and recommended dose of INR731 as a single agent and in combination with standard-of-care androgen receptor pathway inhibitors (ARPIs) in adult patients with metastatic prostate cancer.",[104],"Metastatic Castration-resistant Prostate Cancer (mCRPC)",[28,106,107,108,109,110,111,112],"prostate cancer","mCRPC","castration resistance","androgen receptor pathway inhibitor","ARPI","abiraterone","enzalutamide","2026-05-27",{"date":115,"type":116},"2026-05-28","ACTUAL",{"date":118,"type":116},"2026-05-25",{"date":120,"type":98},"2030-06-03",{"name":44,"class":6},2]